Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 121

Similar articles for PubMed (Select 20488485)

2.

Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program.

Tosoian JJ, Loeb S, Kettermann A, Landis P, Elliot DJ, Epstein JI, Partin AW, Carter HB, Sokoll LJ.

J Urol. 2010 Feb;183(2):534-8. doi: 10.1016/j.juro.2009.10.003. Epub 2009 Dec 14.

PMID:
20006883
3.

Re: Felix K. Chun, Alexandre de la Taille, Hendrik van Poppel, et al. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol 2009;56:659-68.

Morote J.

Eur Urol. 2010 Jan;57(1):e1; author reply e2-3. doi: 10.1016/j.eururo.2009.09.041. Epub 2009 Oct 9. No abstract available.

PMID:
19853371
4.

Re: Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails. A. S. Duffield, T. K. Lee, H. Miyamoto, H. B. Carter and J. I. Epstein. J Urol 2009; 182: 2274-2278.

Lawrentschuk N, Fleshner NE.

J Urol. 2010 May;183(5):2099. doi: 10.1016/j.juro.2010.01.038. Epub 2010 Mar 19. No abstract available.

PMID:
20303514
5.

Urinary PCA3 score predicts prostate cancer multifocality.

Vlaeminck-Guillem V, Devonec M, Colombel M, Rodriguez-Lafrasse C, Decaussin-Petrucci M, Ruffion A.

J Urol. 2011 Apr;185(4):1234-9. doi: 10.1016/j.juro.2010.11.072. Epub 2011 Feb 22.

PMID:
21334023
6.

External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome.

Auprich M, Haese A, Walz J, Pummer K, de la Taille A, Graefen M, de Reijke T, Fisch M, Kil P, Gontero P, Irani J, Chun FK.

Eur Urol. 2010 Nov;58(5):727-32. doi: 10.1016/j.eururo.2010.06.038. Epub 2010 Jul 3.

PMID:
20619529
7.

Re: Validation of the Partin nomogram for prostate cancer in a national sample: J. B. Yu, D. V. Makarov, R. Sharma, R. E. Peschel, A. W. Partin and C. P. Gross J Urol 2010; 183: 105-111.

Ozcan MF, Akbulut Z, Canda AE, Kilic M, Duran E, Balbay MD.

J Urol. 2010 Oct;184(4):1571-2; author reply 1572-3. doi: 10.1016/j.juro.2010.06.029. Epub 2010 Aug 21. No abstract available.

PMID:
20732697
8.

Editorial comment on: Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram.

Briganti A.

Eur Urol. 2009 Oct;56(4):667-8. doi: 10.1016/j.eururo.2009.03.030. Epub 2009 Mar 13. No abstract available.

PMID:
19304374
9.

Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram.

Chun FK, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Abbou CC, Stillebroer AB, van Gils MP, Schalken JA, Fradet Y, Marks LS, Ellis W, Partin AW, Haese A.

Eur Urol. 2009 Oct;56(4):659-67. doi: 10.1016/j.eururo.2009.03.029. Epub 2009 Mar 13.

PMID:
19304372
10.

Molecular PCA3 diagnostics on prostatic fluid.

van Gils MP, Cornel EB, Hessels D, Peelen WP, Witjes JA, Mulders PF, Rittenhouse HG, Schalken JA.

Prostate. 2007 Jun 1;67(8):881-7.

PMID:
17440939
11.

PCA3: a molecular urine assay for predicting prostate biopsy outcome.

Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, Ellis WJ, Marks LS, Fradet Y, Rittenhouse H, Groskopf J.

J Urol. 2008 Apr;179(4):1587-92. doi: 10.1016/j.juro.2007.11.038. Epub 2008 Mar 4.

PMID:
18295257
12.

PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance.

Nakanishi H, Groskopf J, Fritsche HA, Bhadkamkar V, Blase A, Kumar SV, Davis JW, Troncoso P, Rittenhouse H, Babaian RJ.

J Urol. 2008 May;179(5):1804-9; discussion 1809-10. doi: 10.1016/j.juro.2008.01.013. Epub 2008 Mar 18.

PMID:
18353398
13.

Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.

Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Abbou CC, Remzi M, Tinzl M, Feyerabend S, Stillebroer AB, van Gils MP, Schalken JA.

Eur Urol. 2008 Nov;54(5):1081-8. doi: 10.1016/j.eururo.2008.06.071. Epub 2008 Jun 26.

PMID:
18602209
15.

PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.

Whitman EJ, Groskopf J, Ali A, Chen Y, Blase A, Furusato B, Petrovics G, Ibrahim M, Elsamanoudi S, Cullen J, Sesterhenn IA, Brassell S, Rittenhouse H, Srivastava S, McLeod DG.

J Urol. 2008 Nov;180(5):1975-8; discussion 1978-9. doi: 10.1016/j.juro.2008.07.060. Epub 2008 Sep 17.

PMID:
18801539
16.

Development, validation, and head-to-head comparison of logistic regression-based nomograms and artificial neural network models predicting prostate cancer on initial extended biopsy.

Kawakami S, Numao N, Okubo Y, Koga F, Yamamoto S, Saito K, Fujii Y, Yonese J, Masuda H, Kihara K, Fukui I.

Eur Urol. 2008 Sep;54(3):601-11. doi: 10.1016/j.eururo.2008.01.017. Epub 2008 Jan 15.

PMID:
18207312
18.
19.

Re: Tertiary Gleason patterns and biochemical recurrence after prostatectomy: proposal for a modified Gleason scoring system. B. J. Trock, C. C. Guo, M. L. Gonzalgo, A. Magheli, S. Loeb and J. I. Epstein. J Urol 2009; 182: 1364-1370.

Ikenberg K, Zimmermann AK, Kristiansen G.

J Urol. 2010 May;183(5):2100; author reply 2100-1. doi: 10.1016/j.juro.2010.01.037. Epub 2010 Mar 31. No abstract available.

PMID:
20359717
20.

Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results.

van Gils MP, Hessels D, Hulsbergen-van de Kaa CA, Witjes JA, Jansen CF, Mulders PF, Rittenhouse HG, Schalken JA.

Prostate. 2008 Aug 1;68(11):1215-22. doi: 10.1002/pros.20781.

PMID:
18500693
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk